HAS2 and prostate carcinoma: Overexpression of either HAS2 or HAS3 in several tumour types such as prostate cancer [5], breast cancer [6,7], osteosarcoma [8] and colon carcinoma [9] is known to be associated with higher malignancy or metastasis.